Biliverdin Reductase A in Chronic Hepatitis C Virus Infection
Recruitment status was Recruiting
In this project, the investigators aim to study the role of biliverdin reductase A (BLVRA) in HCV infected patients prior and during/after standard antiviral therapy in association with viral clearance, disease progression and treatment response and in comparison with healthy subjects.
Hepatitis C Virus Infection
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Biliverdin Reductase A in Chronic Hepatitis C Virus Infection|
- To assess differences in BLVRA expression in the liver and PBMC in HCV infected patients in responders and non-responders to standard antiviral therapy. [ Time Frame: 72 weeks ] [ Designated as safety issue: No ]
- To analyze the association of genetic polymorphisms of BLVRA with disease progression and treatment response in HCV infected patients. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
peripheral blood, liver biopsy
|Study Start Date:||June 2010|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
|HCV infected patients|
- To analyze biliverdin reductase (BLVRA) expression in the liver of HVC infected patients undergoing liver biopsy followed by standard antiviral treatment (peg-interferon plus ribavirin combination therapy) and patients with other forms of liver diseases undergoing liver biopsy as controls.
- To analyze BLVRA expression in peripheral blood leukocytes (PBL) of therapeutically naïve HCV patients, during/after standard antiviral therapy and healthy controls.
- To analyze BVLRA genetic polymorphisms both in HCV infected patients and healthy controls.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01112033
|Contact: Iva Subhanova||Iva.Subhanova@seznam.cz|
|Contact: Libor Vitek, Prof., MD.,PhD.||email@example.com|
|Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague||Recruiting|
|Prague, Czech Republic, 128 60|
|Contact: Iva Subhanova Iva.Subhanova@seznam.cz|
|Contact: Libor Vitek, Prof.,MD, PhD. firstname.lastname@example.org|
|Principal Investigator: Iva Subhanova|
|Principal Investigator:||Iva Subhanova||Charles University|